No Data
Selling Ocular Therapeutix Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
H.C. Wainwright Remains a Buy on Harrow Health (HROW)
Dole Posts Downbeat Q1 Earnings, Joins Ocular Therapeutix And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Express News | Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Ocular Therapeutix Price Target Maintained With a $18.00/Share by Needham
Chardan Capital Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21